Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bisabolol nanocapsule hydrogel for chronic hand eczema
IRCT20200115046143N2Phase 2Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of alpha-bisabolol and fluocinolone in chronic hand dermatitis (CHE) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Severity of pruritus and Severity of skin lesions. Started Nov 2021; status: completed.
02
Drugs
alpha-bisabololfluocinolone
03
Conditions
chronic hand dermatitis (CHE)
Beyond the preview
Go deeper on IRCT20200115046143N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200115046143N2.